Association of Yersinia Infection With Kawasaki Disease: A Prospective Multicenter Cohort Study.


Journal

The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858

Informations de publication

Date de publication:
01 Dec 2023
Historique:
medline: 16 11 2023
pubmed: 19 9 2023
entrez: 19 9 2023
Statut: ppublish

Résumé

Yersinia infection is known to present with Kawasaki disease (KD)-like symptoms although differentiating the 2 has been a challenge. The present study aimed to describe the clinical characteristics and prevalence of Yersinia infection presenting with KD-like symptoms. The present, prospective, multicenter study enrolled patients who received a diagnosis of KD between January 2021 and January 2022 at 2 hospitals in Tokyo. Stool samples were collected within 3 days of the start of KD treatment, and cultures were performed for Yersinia . Clinical history and symptoms suggestive of Yersinia infection were also evaluated. During the study period, 141 KD patients were screened and 117 patients with evaluable stool samples were registered. Only 1 patient was positive for Yersinia pseudotuberculosis , which was detected from both stool and blood cultures. The patient was refractory to KD treatment but improved after initiation of appropriate antibiotic therapy. Routine screening for Yersinia is not appropriate for patients with KD and should be limited to certain patients in high-risk areas and those who are refractory to the standard KD treatment.

Sections du résumé

BACKGROUND BACKGROUND
Yersinia infection is known to present with Kawasaki disease (KD)-like symptoms although differentiating the 2 has been a challenge. The present study aimed to describe the clinical characteristics and prevalence of Yersinia infection presenting with KD-like symptoms.
METHODS METHODS
The present, prospective, multicenter study enrolled patients who received a diagnosis of KD between January 2021 and January 2022 at 2 hospitals in Tokyo. Stool samples were collected within 3 days of the start of KD treatment, and cultures were performed for Yersinia . Clinical history and symptoms suggestive of Yersinia infection were also evaluated.
RESULTS RESULTS
During the study period, 141 KD patients were screened and 117 patients with evaluable stool samples were registered. Only 1 patient was positive for Yersinia pseudotuberculosis , which was detected from both stool and blood cultures. The patient was refractory to KD treatment but improved after initiation of appropriate antibiotic therapy.
CONCLUSIONS CONCLUSIONS
Routine screening for Yersinia is not appropriate for patients with KD and should be limited to certain patients in high-risk areas and those who are refractory to the standard KD treatment.

Identifiants

pubmed: 37725804
doi: 10.1097/INF.0000000000004084
pii: 00006454-202312000-00003
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1041-1044

Informations de copyright

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors have no funding or conflicts of interest to disclose.

Références

McCrindle BW, Rowley AH, Newburger JW, et al.; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927–e999.
Galindo CL, Rosenzweig JA, Kirtley ML, et al. Pathogenesis of Y. enterocolitica and Y. pseudotuberculosis in human yersiniosis. J Pathog. 2011;2011:182051.
Konishi N, Baba K, Abe J, et al. A case of Kawasaki disease with coronary artery aneurysms documenting Yersinia pseudotuberculosis infection. Acta Paediatr. 1997;86:661–664.
Horinouchi T, Nozu K, Hamahira K, et al. Yersinia pseudotuberculosis infection in Kawasaki disease and its clinical characteristics. BMC Pediatr. 2015;15:177.
Feeney CC, Ajagbe OA, Suryadevara M. Yersinia enterocolitica infection presenting as incomplete Kawasaki disease: 2 cases and a review of the literature. J Pediatric Infect Dis Soc. 2021;10:217–219.
Haidar-Alame S, Raudszus A, Sahai S, et al. A child with Kawasaki disease and Yersinia enterocolitica infection. Glob Pediatr Health. 2015;2:2333794X1559156–233379415591563.
Ohnishi T, Sato S, Kinoshita K, et al. Case of intravenous immunoglobulin-resistant Kawasaki disease with Yersinia enterocolitica enterocolitis successfully treated with cefotaxime following infliximab and cyclosporine. J Pediatric Infect Dis Soc. 2021;10:225–226.
Hassan SM, Doolittle BR. A case of Yersinia enterocolitica mimicking Kawasaki disease. Rheumatology (Oxford). 2009;48:857–858.
Hayashi H, Uda K, Akamine K, et al. A 15-month-old boy with Kawasaki disease-like symptoms. Pediatr Infect Dis J. 2020;40:173–174.
Alfakeekh K, Azar M, Sowailmi BA, et al. Immunosuppressive burden and risk factors of infection in primary childhood nephrotic syndrome. J Infect Public Health. 2019;12:90–94.
Murdaca G, Spanò F, Contatore M, et al. Infection risk associated with anti-TNF-α agents: a review. Expert Opin Drug Saf. 2015;14:571–582.
Suzuki H, Terai M, Hamada H, et al. Cyclosporin a treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J. 2011;30:871–876.
Kobayashi T, Ayusawa M, Suzuki H, et al. Revision of diagnostic guidelines for Kawasaki disease (6th revised edition). Pediatr Int. 2020;62:1135–1138.
Tsubokura M, Otsuki K, Sato K, et al. [Distribution of Yersinia pseudotuberculosis in Japan and epidemiology of human infection]. Kansenshogaku Zasshi. 1987;61:737–745.
Fukushima H. Epidemiology of pathogenic Yersinia and their detection method. Japan J Food Microbiol. 2011;28:104–113.
Tsubokura M, Otsuki K, Sato K, et al. Special features of distribution of Yersinia pseudotuberculosis in Japan. J Clin Microbiol. 1989;27:790–791.
Colomba C, La Placa S, Saporito L, et al. Intestinal involvement in Kawasaki disease. J Pediatr. 2018;202:186–193.
Baker AL, Lu M, Minich LL, et al.; Pediatric Heart Network Investigators. Associated symptoms in the ten days before diagnosis of Kawasaki disease. J Pediatr. 2009;154:592–595.e2.
Yun SH, Yang NR, Park SA. Associated symptoms of Kawasaki disease. Korean Circ J. 2011;41:394–398.

Auteurs

Hiroshi Hayashi (H)

From the Department of General Pediatrics.
Clinical Research Support Center, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.

Kazuhiro Uda (K)

Division of Infectious Diseases, Department of Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Department of Pediatrics, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.

Yumi Araki (Y)

From the Department of General Pediatrics.

Shogo Akahoshi (S)

Clinical Research Support Center, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Department of Pediatrics, Tokyo Metropolitan Tama-Hokubu Medical Center, Tokyo, Japan.

Miki Tanaka (M)

Department of Pediatrics, Tokyo Metropolitan Tama-Hokubu Medical Center, Tokyo, Japan.

Koichi Miyata (K)

Department of Cardiology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.

Hiroshi Hataya (H)

From the Department of General Pediatrics.

Masaru Miura (M)

Clinical Research Support Center, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Department of Cardiology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH